Long-Term Safety and Efficacy Study of Oral BG00012 Monotherapy in Relapsing-Remitting Multiple Sclerosis

This study is ongoing, but not recruiting participants.
Sponsor:
Information provided by:
Biogen Idec
ClinicalTrials.gov Identifier:
NCT00835770
First received: February 2, 2009
Last updated: September 12, 2013
Last verified: March 2012
  Purpose

The purpose of this study is to evaluate the long-term safety and efficacy of BG00012.


Condition Intervention Phase
Relapsing-Remitting Multiple Sclerosis
Drug: BG00012
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety Study
Intervention Model: Parallel Assignment
Masking: Single Blind (Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Dose-Blind, Multicenter, Extension Study to Determine the Long-Term Safety and Efficacy of Two Doses of BG00012 Monotherapy in Subjects With Relapsing-Remitting Multiple Sclerosis

Resource links provided by NLM:


Further study details as provided by Biogen Idec:

Primary Outcome Measures:
  • To evaluate the long-term safety profile of BG00012 [ Time Frame: Up to 5 years ] [ Designated as safety issue: Yes ]

Secondary Outcome Measures:
  • To evaluate the long-term efficacy of BG00012 on clinical outcomes and MS brain lesions on MRI scans; and effects of BG00012 on quality of life measurements [ Time Frame: Up to 5 years ] [ Designated as safety issue: Yes ]

Enrollment: 1700
Study Start Date: February 2009
Estimated Study Completion Date: June 2016
Estimated Primary Completion Date: June 2016 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 1
BG00012 240mg BID
Drug: BG00012
240mg (two-120mg capsules) orally twice a day; 240mg (two-120mg capsules) orally three times a day. Up to 5 years in duration.
Experimental: 2
BG00012 240mg TID
Drug: BG00012
240mg (two-120mg capsules) orally twice a day; 240mg (two-120mg capsules) orally three times a day. Up to 5 years in duration.

Detailed Description:

Multiple sclerosis (MS) is a chronic disease of the central nervous system that affects approximately 400,000 persons in North America and 365,000 persons in Europe. It is predominantly a disease of young adults, primarily women, with disease onset typically occurring between the ages of 20 and 40.

  Eligibility

Ages Eligible for Study:   19 Years to 58 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

-Subjects who participated in and completed as per protocol previous BG00012 clinical studies 109MS301 or 109MS302.

Exclusion Criteria:

  • Any significant change in medical history from 109MS301 or 109MS302 that would have excluded subject's participation from their previous study.
  • Subjects from 109MS301 or 109MS302 who discontinued oral study treatment due to an AE or due to reasons other than protocol-defined relapse/disability progression.
  • Subjects from 109MS301 or 109MS302 who discontinued study treatment due to disability progression or relapses and did not follow the modified visit schedule up to Week 96.
  • Other protocol defined inclusion/exclusion criteria may apply.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00835770

  Hide Study Locations
Locations
United States, Alabama
Research Site
Birmingham, Alabama, United States
Research Site
Huntsville, Alabama, United States
United States, Arizona
Research Site
Gilbert, Arizona, United States
Research Site
Phoenix, Arizona, United States
United States, California
Research Site
Loma Linda, California, United States
Research Site
Sacramento, California, United States
United States, Colorado
Research Site
Boulder, Colorado, United States
Research Site
Colorado Springs, Colorado, United States
Research Site
Fort Collins, Colorado, United States
United States, Connecticut
Research Site
Fairfield, Connecticut, United States
United States, District of Columbia
Research Site
Washington, District of Columbia, United States
United States, Florida
Research Site
Maitland, Florida, United States
Research Site
Naples, Florida, United States
Research Site
Saint Petersburg, Florida, United States
Research Site
Sarasota, Florida, United States
Research Site
Tampa, Florida, United States
Research Site
Vero Beach, Florida, United States
United States, Georgia
Research Site
Atlanta, Georgia, United States
United States, Illinois
Research Site
Evanston, Illinois, United States
United States, Indiana
Research Site
Fort Wayne, Indiana, United States
Research Site
Indianapolis, Indiana, United States
United States, Iowa
Research Site
Des Moines, Iowa, United States
United States, Kansas
Research Site
Kansas City, Kansas, United States
Research Site
Wichita, Kansas, United States
United States, Kentucky
Research Site
Lexington, Kentucky, United States
Research Site
Louisville, Kentucky, United States
United States, Louisiana
Research Site
Shreveport, Louisiana, United States
United States, Maryland
Research Site
Baltimore, Maryland, United States
United States, Massachusetts
Research Site
Boston, Massachusetts, United States
Research Site
Hopedale, Massachusetts, United States
Research Site
Springfield, Massachusetts, United States
United States, Michigan
Research Site
Farmington Hills, Michigan, United States
United States, Minnesota
Research Site
Minneapolis, Minnesota, United States
United States, Missouri
Research Site
Saint Louis, Missouri, United States
United States, New York
Research Site
Albany, New York, United States
Research Site
Amherst, New York, United States
Research Site
Buffalo, New York, United States
Research Site
Patchogue, New York, United States
United States, North Carolina
Research Site
Charlotte, North Carolina, United States
Research Site
Raleigh, North Carolina, United States
United States, Ohio
Research Site
Bellevue, Ohio, United States
Research Site
Cleveland, Ohio, United States
Research Site
Columbus, Ohio, United States
Research Site
Dayton, Ohio, United States
United States, Oregon
Research Site
Medford, Oregon, United States
Research Site
Portland, Oregon, United States
United States, Pennsylvania
Research Site
Erie, Pennsylvania, United States
Research Site
Philadelphia, Pennsylvania, United States
Research Site
Pittsburg, Pennsylvania, United States
Research Site
Pittsburgh, Pennsylvania, United States
United States, Rhode Island
Research Site
East Providence, Rhode Island, United States
United States, Tennessee
Research Site
Cordova, Tennessee, United States
Research Site
Franklin, Tennessee, United States
Research Site
Knoxville, Tennessee, United States
Research Site
Nashville, Tennessee, United States
United States, Texas
Research Site
Dallas, Texas, United States
Research Site
Houston, Texas, United States
United States, Utah
Research Site
Salt Lake City, Utah, United States
United States, Vermont
Research Site
Burlington, Vermont, United States
United States, Virginia
Research Site
Newport News, Virginia, United States
United States, Washington
Research Site
Seattle, Washington, United States
Research Site
Tacoma, Washington, United States
United States, Wisconsin
Research Site
Madison, Wisconsin, United States
Australia, New South Wales
Research Site
Camperdown, New South Wales, Australia
Research Site
Chatswood, New South Wales, Australia
Research Site
Kogarah, New South Wales, Australia
Research Site
New Lambton Heights, New South Wales, Australia
Australia, Victoria
Research Site
Fitzroy, Victoria, Australia
Research Site
West Heidelberg, Victoria, Australia
Austria
Research Site
Graz, Styria, Austria
Research Site
Linz, Upper Austria, Austria
Research Site
Wien, Vienna, Austria
Canada, Alberta
Research Site
Edmonton, Alberta, Canada
Canada, Nova Scotia
Research Site
Halifax, Nova Scotia, Canada
Canada, Ontario
Research Site
London, Ontario, Canada
Research Site
Ottawa, Ontario, Canada
Canada, Quebec
Research Site
Lévis, Quebec, Canada
Research Site
Montreal, Quebec, Canada
Canada, Saskatchewan
Research Site
Regina, Saskatchewan, Canada
Croatia
Research Site
Zagreb, Croatia
Czech Republic
Research Site
Brno, Jihocesky Kraj, Czech Republic
Research Site
Jihlava, Kraj Vysocina, Czech Republic
Research Site
Olomouc, Olomoucký kraj, Czech Republic
Research Site
Praha 5, Praha, Czech Republic
Research Site
Teplice, Severocesky Kraj, Czech Republic
Research Site
Opava, Czech Republic
Research Site
Ostrava - Vítkovice, Czech Republic
Research Site
Ostrava-Moravska Ostrava, Czech Republic
Research Site
Praha 2, Czech Republic
Estonia
Research Site
Parnu, Estonia
Research Site
Tallinn, Estonia
Research Site
Tartu, Estonia
Germany
Research Site
Bamberg, Bayern, Germany
Research Site
Erlangen, Bayern, Germany
Research Site
München, Bayern, Germany
Research Site
Regensburg, Bayern, Germany
Research Site
Hannover, Niedersachsen, Germany
Research Site
Osnabrück, Niedersachsen, Germany
Research Site
Westerstede, Niedersachsen, Germany
Research Site
Bochum, Nordrhein-westfalen, Germany
Research Site
Düsseldorf, Nordrhein-westfalen, Germany
Research Site
Essen, Nordrhein-westfalen, Germany
Research Site
Minden, Nordrhein-westfalen, Germany
Research Site
Halle, Sachsen-anhalt, Germany
Research Site
Dresden, Sachsen, Germany
Research Site
Leipzig, Sachsen, Germany
Research Site
Berlin, Germany
Research Site
Erbach, Germany
Research Site
Hamburg, Germany
Greece
Research Site
Athens, Attica, Greece
Research Site
Thessaloniki, Macedoni, Greece
Guatemala
Research Site
Guatemala, Guatemala
Research Site
Guatemala City, Guatemala
Italy
Research Site
Roma, Italy
Latvia
Research Site
Riga, Latvia
Mexico
Research Site
Mexico, Distrito Federal, Mexico
Research Site
San Luis Potosi, Mexico
Netherlands
Research Site
Sittard-Geleen, Limburg, Netherlands
New Zealand
Research Site
Grafton, Auckland, New Zealand
Research Site
Christchurch, New Zealand
Research Site
Hamilton, New Zealand
Poland
Research Site
Wroclaw, Dolnoslaskie, Poland
Research Site
Lódz, Lodzkie, Poland
Research Site
Warszawa, Mazowieckie, Poland
Research Site
Bialystok, Podlaskie, Poland
Research Site
Gdansk, Pomorskie, Poland
Research Site
Katowice, Slaskie, Poland
Research Site
Plewiska K/Poznania, Wielkopolskie, Poland
Research Site
Szczecin, Zachodniopomorskie, Poland
Research Site
Lublin, Poland
Puerto Rico
Research Site
Guaynabo, Puerto Rico
Romania
Research Site
Cluj-Napoca, Cluj, Romania
Research Site
Târgu Mures, Mures, Romania
Research Site
Timisoara, Timis, Romania
Research Site
Bucuresti, Romania
Serbia
Research Site
Kragujevac, Serbia
Research Site
Nis, Serbia
Slovakia
Research Site
Bratislava, Slovakia
Research Site
Martin, Žilina, Slovakia
South Africa
Research Site
Rosebank, Gauteng, South Africa
Research Site
Durban, KwaZulu-Natal, South Africa
Research Site
Cape Town, Western Cape, South Africa
Spain
Research Site
Sevilla, Andalucía, Spain
Research Site
Córdoba, Cordoba, Spain
Research Site
Barcelona, Spain
Research Site
Madrid, Spain
Switzerland
Research Site
Basel, Switzerland
Ukraine
Research Site
Simferopol, Crimea, Ukraine
Research Site
Kyiv, Kiev, Ukraine
Research Site
Kharkiv, Ukraine
Research Site
Kyiv, Ukraine
Research Site
Lviv, Ukraine
Research Site
Odessa, Ukraine
United Kingdom
Research Site
London, England, United Kingdom
Research Site
Newcastle upon Tyne, England, United Kingdom
Research Site
Oxford, England, United Kingdom
Research Site
Sheffield, England, United Kingdom
Research Site
Staffordshire, England, United Kingdom
Sponsors and Collaborators
Biogen Idec
  More Information

No publications provided

Responsible Party: Biogen Idec MD, Biogen Idec
ClinicalTrials.gov Identifier: NCT00835770     History of Changes
Other Study ID Numbers: 109MS303
Study First Received: February 2, 2009
Last Updated: September 12, 2013
Health Authority: United States: Food and Drug Administration

Keywords provided by Biogen Idec:
relapsing
multiple sclerosis
remitting
oral

Additional relevant MeSH terms:
Dimethyl fumarate
Multiple Sclerosis
Sclerosis
Multiple Sclerosis, Relapsing-Remitting
Demyelinating Autoimmune Diseases, CNS
Autoimmune Diseases of the Nervous System
Nervous System Diseases
Demyelinating Diseases
Autoimmune Diseases
Immune System Diseases
Pathologic Processes
Dermatologic Agents
Therapeutic Uses
Pharmacologic Actions
Immunosuppressive Agents
Immunologic Factors
Physiological Effects of Drugs
Radiation-Sensitizing Agents

ClinicalTrials.gov processed this record on August 28, 2014